Acetylated K676 TGFBIp as a severity diagnostic blood biomarker for SARS-CoV-2 pneumonia.
Sci Adv
; 6(31)2020 07.
Article
in English
| MEDLINE | ID: covidwho-725277
ABSTRACT
The outbreak of the highly contagious and deadly severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus disease 2019 (COVID-19), has posed a serious threat to public health across the globe, calling for the development of effective diagnostic markers and therapeutics. Here, we report a highly reliable severity diagnostic biomarker, acetylated 676th lysine transforming growth factor-beta-induced protein (TGFBIp K676Ac). TGFBIp K676Ac was consistently elevated in the blood of patients with SARS-CoV-2 pneumonia (n = 113), especially in patients in the intensive care unit (ICU) compared to non-ICU patients. Patients' blood samples showed increased cytokines and lymphopenia, which are exemplary indicators of SARS-CoV-2 pneumonia. Treatment with TGFBIp neutralizing antibodies suppressed the cytokine storm. The increased level of TGFBIp K676Ac in ICU patients suggests the promise of this protein as a reliable severity diagnostic biomarker for severe SARS-CoV-2 disease.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Respiratory Insufficiency
/
Leukocytes, Mononuclear
/
Protein Processing, Post-Translational
/
Extracellular Matrix Proteins
/
Transforming Growth Factor beta
/
Coronavirus Infections
/
Betacoronavirus
/
Cytokine Release Syndrome
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Language:
English
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS